Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study

Authors
Molina, Luis; Recinos, Byron; Paz, Bezner; Rovelo, Mauricio; Elias Rodriguez, Fanny Elizabeth; Calderón, José; Arellano, Arturo; Pomata, Santiago; Rey, María Verónica; Pérez Lloret, Santiago
Publication Year
2016
Language
English
Format
article
Status
Published version
Description
Background and Objectives The first weeks of treatment with antipsychotics are important for the development of their long-term efficacy. The objective of this study was to identify factors related to early clinical effects and quality of life (QoL) improvements with quetiapine extended-release (XR). Methods Six hundred and sixty-five patients starting with quetiapine XR were followed up for 8 weeks (schizophrenia = 153, major depression = 200, bipolar depression = 252, other psychiatric conditions = 60). Clinical effects were assessed by the Clinical Global Impression of Change scale (CGI-C), QoL by the visual analog scale (VAS) of the EQ-5D (QoL-VAS), and adherence by the Moriksy scale. Adverse events were explored: movement disorders by the UKU and Simpson-Angus scales, weight gain by calibrated balances, and diurnal somnolence by the Epworth Somnolence Scale (ESS). Results The mean dose of quetiapine XR during follow-up was 195.6 ± 154.8 mg/day. CGI and QoL-VAS scores improved significantly at week 8 by 2.7 ± 0.1 points and 25.1 ± 0.9 points. Adverse events were observed in 34 and 26 % of patients at weeks 4 and 8, respectively. A significant reduction in ESS score was also observed at week 8. Factors independently associated with change in QoL-VAS ≥20 points (n = 292, 43 %) were female gender, more severe disease at baseline, higher antipsychotic dose during follow-up, and improvements in somnolence. Factors independently associated with clinically significant improvement (CGI-C ≥5, n = 610, 93 %) were greater change in QoL-VAS, less frequent movement disorders at baseline, and lack of adverse events during follow-up, especially somnolence. Conclusions Results from this real-setting, large observational study in Central America suggest that disease severity at baseline, gender, antipsychotic dose, and occurrence of adverse reactions has a significant impact on the early clinical effects of quetiapine XR.
Fil: Molina, Luis. Clínica de Especialidades Altamira; Nicaragua
Fil: Recinos, Byron. Universidad San Carlos de Guatemala; Guatemala
Fil: Paz, Bezner. Hospital Juan de Dios de San Pedro; Honduras
Fil: Rovelo, Mauricio. Instituto de Salud Mental; Honduras
Fil: Elias Rodriguez, Fanny Elizabeth. Colonia Médica; El Salvador
Fil: Calderón, José. Clínica de la Conducta; Panamá
Fil: Arellano, Arturo. Corporación Farmacéutica Recalcine; Costa Rica
Fil: Pomata, Santiago. Corporación Farmacéutica Recalcine; Costa Rica
Fil: Rey, María Verónica. Etymos Consulting Group; Argentina
Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; Argentina
Subject
Ezquisofrenia
Depresion
Quetipina
Efectos tempranos
Medicina Critica y de Emergencia
Medicina Clínica
CIENCIAS MÉDICAS Y DE LA SALUD
Access level
Restricted access
License
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repository
CONICET Digital (CONICET)
Institution
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identifier
oai:ri.conicet.gov.ar:11336/41808